Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence<i>in situ</i>hybridization (FISH) to select the optimal patients for matched therapy?

Chae, Young Kwang; Arya, Ayush; Chiec, Lauren; Shah, Hiral; Rosenberg, Ari J.; Patel, Sandip Pravin; Raparia, Kirtee; Choi, Jaehyuk; Wainwright, Derek A.; Villaflor, Victoria M.; Cristofanilli, Massimo; Giles, Francis J.

doi:10.18632/oncotarget.19809

Cited by 20 publications

(19 citation statements)

References 240 publications

(203 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several molecules targeting the MET/HGF signaling have been developed, including monoclonal antibodies [against either HGF (Rilotumumab), or MET (Onartuzumab)] and MET small kinase inhibitors (Foretinib). These inhibitors were evaluated in clinical trials as target therapies for metastatic or unresectable gastric cancer[ 157 ]. Unfortunately, negative results were obtained in several phases II and III clinical trials due to a higher rate of serious toxicities or an increase in the number of deaths[ 158 ].…”

Section: Clinical Implications Of Molecular Gc Classification: Impactmentioning

confidence: 99%

New therapeutic options opened by the molecular classification of gastric cancer

Chivu‐Economescu¹,

Matei²,

Necula³

et al. 2018

WJG

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most lethal and aggressive cancers, being the third cause of cancer related death worldwide. Even with radical gastrectomy and the latest generation of molecular chemotherapeutics, the numbers of recurrence and mortality remains high. This is due to its biological heterogeneity based on the interaction between multiple factors, from genomic to environmental factors, diet or infections with various pathogens. Therefore, understanding the molecular characteristics at a genomic level is critical to develop new treatment strategies. Recent advances in GC molecular classification provide the unique opportunity to improve GC therapy by exploiting the biomarkers and developing novel targeted therapy specific to each subtype. This article highlights the molecular characteristics of each subtype of gastric cancer that could be considered in shaping a therapeutic decision, and also presents the completed and ongoing clinical trials addressed to those targets. The implementation of the novel molecular classification system will allow a preliminary patient selection for clinical trials, a mandatory issue if it is desired to test the efficacy of a certain inhibitor to the given target. This will represent a substantial advance as well as a powerful tool for targeted therapy. Nevertheless, translating the scientific results into new personalized treatment opportunities is needed in order to improve clinical care, the survival and quality of life of patients with GC.

show abstract

Section: Clinical Implications Of Molecular Gc Classification: Impactmentioning

confidence: 99%

New therapeutic options opened by the molecular classification of gastric cancer

Chivu‐Economescu¹,

Matei²,

Necula³

et al. 2018

WJG

View full text Add to dashboard Cite

show abstract

“…Programmed cell death protein 1 (PD‐1) and programmed cell‐death 1‐ligand 1 (PD‐L1) are transmembrane proteins that are important examples of proteins mediating such interactions. PD‐1 is expressed on the surface of B‐cells, T‐cells, and myeloid cells and functions as a checkpoint protein that is responsible for downregulating the immune system to protect the host from autoreactive T‐cells . Furthermore, the binding of PD‐1 to PD‐L1 in normal cells inhibits TCR‐mediated activation of interleukin (IL‐2) production and T‐cell proliferation to effectively prevent autoimmune disease.…”

Section: Emerging Prognostic Biomarkersmentioning

confidence: 99%

Overview of established and emerging immunohistochemical biomarkers and their role in correlative studies in MRI

Alvi

Gupta

Borok

et al. 2019

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Clinical practice in radiology and pathology requires professional expertise and many years of training to visually evaluate and interpret abnormal phenotypic features in medical images and tissue sections to generate diagnoses that guide patient management and treatment. Recent advances in digital image analysis methods and machine learning have led to significant interest in extracting additional information from medical and digital whole‐slide images in radiology and pathology, respectively. This has led to significant interest and research in radiomics and pathomics to correlate phenotypic features of disease with image analytics in order to identify image‐based biomarkers. The expanding role of big data in radiology and pathology parallels the development and role of immunohistochemistry (IHC) in the daily practice of pathology. IHC methods were initially developed to provide additional information to help classify tumors and then transformed into an indispensable tool to guide treatment in many types of cancer. IHC markers are used in daily practice to identify specific types of cells and highlight their distributions in tissues in order to distinguish benign from neoplastic cells, determine tumor origin, subclassify neoplasms, and support and confirm diagnoses. In this regard, radiomics, pathomics, and IHC methods are very similar since they enable the extraction of image‐based features to characterize various properties of diseases. Due to the dramatic advancements in recent radiomics research, we provide a brief overview of the role of established and emerging IHC biomarkers in various tumor types that have been correlated with radiologic biomarkers to improve diagnostic accuracy, predict prognosis, guide patient management, and select treatment strategies. Level of Evidence: 5 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2020;51:341–354.

show abstract

“…In this context, MAP DNA can be identified especially by PCR. Thus far, novel laboratory techniques (Chae et al, 2017) Southern Blot hybridization, Immunohistochemistry (IHC), introduced by Coons (Coons et al, 1941) in 1941, In-situ hybridization (ISH), described in the year 1969 by Joseph G. Gall (Gall et al, 1969) Fidleret al, 1994;Hulten et al, 2001;Ryan et al, 2002;Bull et al, 2003;Autschbach et al, 2005;Sechi et al, 2005;Romero et al, 2005;Szkaradkiewicz et al, 2007;Kirkwood et al, 2009;Mendoza et al, 2010;Tuci et al, 2011;Lee et al, 2011;Nazareth et al, 2015;Timms et al, 2016;Khan et al, 2016;Zamani et al, 2017) analyzed, are presented by the …”

Section: The Data Of the Studies Analyzedmentioning

confidence: 99%

Mycobacterium Avium Subspecies Paratuberculosis

Barukčić¹

2018

MHS

View full text Add to dashboard Cite

Objective: This systematic review assesses the causal relationship between Mycobacterium avium subspecies paratuberculosis (MAP) and Crohn's disease (CD). Methods:A systematic review and meta-analysis of some impressive PCR based studies is provided aimed to answer among other questions the following question. Is there a cause effect relationship between Mycobacterium avium subspecies paratuberculosis and Crohn's disease? The method of the conditio per quam relationship was used to proof the hypothesis whether the presence of Mycobacterium avium subspecies paratuberculosis guarantees the presence of Crohn's disease. In other words, if Crohn's disease is present, then Mycobacterium avium subspecies paratuberculosis is present too. The mathematical formula of the causal relationship k was used to proof the hypothesis, whether there is a cause effect relationship between Mycobacterium avium subspecies paratuberculosis and Crohn's disease. Significance was indicated by a p-value of less than 0.05. Results:The studies analyzed (number of cases and controls N=1076) were able to provide evidence that Mycobacterium avium subspecies paratuberculosis is a necessary condition (conditio sine qua non) and sufficient condition of Crohn's disease. Furthermore, the studies analyzed provide impressive evidence of a cause-effect relationship between Mycobacterium avium subspecies paratuberculosis and Crohn's disease. Conclusion:Mycobacterium avium subspecies paratuberculosis is the cause of Crohn's disease (k=+0.4435, p value < 0.0001).

show abstract

Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescencein situhybridization (FISH) to select the optimal patients for matched therapy?

Cited by 20 publications

References 240 publications

New therapeutic options opened by the molecular classification of gastric cancer

New therapeutic options opened by the molecular classification of gastric cancer

Overview of established and emerging immunohistochemical biomarkers and their role in correlative studies in MRI

Mycobacterium Avium Subspecies Paratuberculosis

Contact Info

Product

Resources

About